169750-57-6

Usage

Uses

Used in Pharmaceutical Industry:
4-Hydroxy-4-methylpiperidine-1-carboxylic acid benzyl ester is used as a chemical intermediate for the synthesis of various drugs, contributing to the development of pharmaceuticals for the treatment of different medical conditions.
Used in Drug Development:
In the field of drug development, 4-Hydroxy-4-methylpiperidine-1-carboxylic acid benzyl ester is utilized as a key component in the formulation of new medications, targeting a range of therapeutic areas.
It is important to handle and store 4-Hydroxy-4-methylpiperidine-1-carboxylic acid benzyl ester with care, as it may be hazardous if not managed properly, ensuring safety in its applications within the pharmaceutical sector.

InChI:InChI=1/C14H19NO3/c1-14(17)7-9-15(10-8-14)13(16)18-11-12-5-3-2-4-6-12/h2-6,17H,7-11H2,1H3

Upstream product

• 19099-93-5 benzyl 4-oxo-1-piperidinecarboxylate 
• 501-53-1 benzyl chloroformate 
• 75-16-1 methylmagnesium bromide 
• 676-58-4 methylmagnesium chloride 
• 917-54-4 methyllithium 
• 626-58-4 4-methylpiperidin 
• 217795-77-2 N-benzyloxycarbonyl-4-methylpiperidine 

Downstream Products

• 1236404-94-6 N-{3-[(4-hydroxy-4-methylpiperidin-1-yl)methyl]-8-methylquinolin-7-yl}-4-[(2S)-tetrahydrofuran-2-ylmethoxy]benzamide 
• 1236404-84-4 N-{3-[(4-hydroxy-4-methylpiperidin-1-yl)methyl]-8-methylquinolin-7-yl}-4-(tetrahydrofuran-3-ylmethoxy)benzamide 
• 3970-68-1 4-methylpiperidin-4-ol 

Relevant academic research and scientific papers

Design, synthesis, and in vitro bioactivity evaluation of fluorine-containing analogues for sphingosine-1-phosphate 2 receptor

Twenty eight new aryloxybenzene analogues were synthesized and their in vitro binding potencies toward S1PR2 were determined using a [32P]S1P competitive binding assay. Out of these new analogues, three compounds, 28c (IC50 = 29.9 ± 3.9 nM), 28e (IC50 = 14.6 ± 1.5 nM), and 28g (IC50 = 38.5 ± 6.3 nM) exhibited high binding potency toward S1PR2 and high selectivity over the other four receptor subtypes (S1PR1, 3, 4, and 5; IC50 > 1000 nM). Each of the three potent compounds 28c, 28e, and 28g contains a fluorine atom that will allow to develop F-18 labeled PET radiotracers for imaging S1PR2.

Oxyfunctionalization of the Remote C?H Bonds of Aliphatic Amines by Decatungstate Photocatalysis

Aliphatic amines, oxygenated at remote positions within the molecule, represent an important class of synthetic building blocks to which there are currently no direct means of access. Reported herein is an efficient and scalable solution that relies upon decatungstate photocatalysis under acidic conditions using either H2O2 or O2 as the terminal oxidant. By using these reaction conditions a series of simple and unbiased aliphatic amine starting materials can be oxidized to value-added ketone products. Lastly, NMR spectroscopy using in situ LED-irradiated samples was utilized to monitor the kinetics of the reaction, thus enabling direct translation of the reaction into flow.

IMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING PHARMACOKINETICS OF DRUG

Imidazole derivatives of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising at least one imidazole derivative are disclosed. The imidazole derivatives are effective to inhibit CYP450 3A and can be used to improve the pharmacokinetics of a drug that is metabolized by CYP450 3A4.

IMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG

The present invention relates to Imidazole Derivatives of Formula (I), and pharmaceutically acceptable salts thereof, wherein A, B, Y, R1 and R2 are as defined herein. The present invention also relates to compositions comprising at least one Imidazole Derivative, and and methods of using the Imidazole Derivatives for inhibiting CYP450 3A. Inhibition of CYP450 3A can be used to improve the pharmacokinetics of a drug that is metabolized by CYP450 3A4.

QUINOLINE DERIVATIVE

The present invention provides a compound having a melanin-concentrating hormone receptor antagonistic action and low toxicity, which is useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

AZAARENE DERIVATIVES

A compound represented by the general formula: wherein X1 represents a nitrogen atom or a group represented by the formula -CR10=; X2 represents a nitrogen atom or a group represented by the formula -CR11=; Y represents an oxygen atom or the like; R1 represents a C1-6 alkoxy group, an optionally substituted C6-10 aryloxy group, a group represented by the formula -NR12aR12b or the like; R2 represents a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like; R3, R4, R5, R6, R7, R8, R10 and R11 each independently represent a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, or the like; R9 represents a group represented by the formula -NR16aR16b or the like; and R12a, R12b, R16a and R16b each independently represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, a salt thereof, or a hydrate of the foregoing.

Biohydroxylations of Cbz-protected alkyl substituted piperidines by Beauveria bassiana ATCC 7159

N-Benzyloxycarbonyl (Cbz) protected piperidines are hydroxylated with greater regioselectivity than the corresponding N-benzoyl analogues when incubated with the fungus Beauveria bassiana ATCC 7159. Cbz-protected piperidines 1-3, 5-7, have been biotransfo